190 related articles for article (PubMed ID: 20414645)
41. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
[TBL] [Abstract][Full Text] [Related]
42. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
Gawrońska-Szklarz B; Adamiak-Giera U; Wyska E; Kurzawski M; Gornik W; Kaldonska M; Drozdzik M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1267-74. PubMed ID: 22418828
[TBL] [Abstract][Full Text] [Related]
43. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
44. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
45. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
[TBL] [Abstract][Full Text] [Related]
46. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.
Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Br J Clin Pharmacol; 2008 May; 65(5):767-74. PubMed ID: 18294333
[TBL] [Abstract][Full Text] [Related]
47. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Isaza C; Henao J; Martínez JH; Sepúlveda Arias JC; Beltrán L
BMC Clin Pharmacol; 2007 Jul; 7():6. PubMed ID: 17623107
[TBL] [Abstract][Full Text] [Related]
48. Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database.
Adachi K; Ohyama K; Tanaka Y; Murayama N; Shimizu M; Saito Y; Yamazaki H
Biol Pharm Bull; 2024; 47(5):1028-1032. PubMed ID: 38797695
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
51. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
52. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
53. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
54. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
[TBL] [Abstract][Full Text] [Related]
56. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Kodaira C; Uchida S; Yamade M; Nishino M; Ikuma M; Namiki N; Sugimoto M; Watanabe H; Hishida A; Furuta T
J Clin Pharmacol; 2012 Mar; 52(3):432-9. PubMed ID: 21415279
[TBL] [Abstract][Full Text] [Related]
57. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
58. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD).
Ward RM; Tammara B; Sullivan SE; Stewart DL; Rath N; Meng X; Maguire MK; Comer GM
Eur J Clin Pharmacol; 2010 Jun; 66(6):555-61. PubMed ID: 20306184
[TBL] [Abstract][Full Text] [Related]
59. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
